Nasal Spray Study in Sjogren's Dry Eye Disease
Completed · Phase 4 · NCT05700422
Conditions: Sjogren's Syndrome, Dry Eye
At a glance
- Research payments reported, 2025
- $9,800
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 39
About the trial
- Sponsor
- University of Pennsylvania (with Oyster Point Pharma, Inc.)
- Tested
- Varenicline Nasal Spray (drug)
- Dates
- Started 2023-05-01; completion 2023-08-31
- Results posted
- Yes
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month. You will also self-administer the nasal spray at home every day, 2 times a day during this month.
From ClinicalTrials.gov, last updated 2024-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Oyster Point Pharma, Inc. reported $9,800 in research payments for this study in 2025 (1 payments).
Products named: Tyrvaya
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.